Fascinating results from Nadia Pillai, using real world data from a Swiss IBD cohort to model the cost-effectiveness of early biologic therapy. Early use of biologics is not cost effective in this cohort, but this outcome changes with biologic price drops or with more careful patient selection.

Avi Dukler describes results from a new serum biomarker panel developed and tested for prediction of endoscopic healing in a cohort study from Leuven, Belgium.

Heike Schmitt describes her work dissecting the immunomodulatory effects of cobitolimod using material from murine studies and a human clinical trial.

Bram Verstockt reports a large, single centre experience of Vedolizumab use in both UC and CD from Leuven, Belgium with interesting findings for endoscopic outcomes as well as therapeutic drug monitoring.

Lara Hart discusses her team’s work capturing faecal calprotectin values in a large cohort of patients with clinically quiescent ulcerative colitis undergoing colonoscopy, and reports test performance for predicting ongoing endoscopic or histologic disease activity.

Monica Boirivant describes the work and the thinking behind her team’s demonstration of distinct subgroups of patients with different IL-13 expression in ulcerative colitis, with distinct clinical and microbial profiles and discusses implications for therapeutics in the context of previous negative anti-IL13 studies.

Julien Verdier reports the work of the team at INSERM, Paris, analysing microRNA expression in faeces and considers the significance of the differences they observed between patients with active disease and controls.

Marieke Barnhoorn discusses the work of the team at Leiden University Medical centre to report efficacy and safety data for patients 4 years after receipt of allogeneic bone marrow-derived mesenchymal stem cells for treatment of Crohn’s disease perianal fistulae.

Bobby Lo discusses his work measuring the impact of IBD on healthcare costs and the wider economy in a Danish cohort and provides some interesting insight into the Danish healthcare model.

Jérémie Lefevre discusses the work of the GETAID surgical group examining post-operative outcomes for a large series of patients undergoing repeat ileocolonic resection and reports some reassuring findings.